Alzinova Ab

Other

Amylonix Ab

Torleif Härd

Anders Sandberg

Mats Sandgren

Stefan Ståhl

John Löfblom

Hanna Lindberg

Benjamin Schmuck

The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid &#x3b2; (A&#x3b2;) peptides (in the following referred to as A&#x3b2;), comprising the amino acid sequence EXXYXXNLXA XQLCAXIXXXED (SEQ ID NO:632). The present disclosure also relates to the use of such A&#x3b2; peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.

Alzheimer A&#x3b2; peptide binding polypeptide

The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to 1:0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications. (FIG.).

Antibody binding nanofibrils

The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Stable amyloid beta monomers and oligomers

Method of immunization for reducing toxic damaged caused by oligomeric form of the amyloid-beta protein with stable amyloid beta monomers and oligomers

The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Growing community of inventors

Uppsala, Sweden

Torleif Härd